Skip to content
Business Company News, Medical Health Aged Care

DIAG-NOSE.IO ANNOUNCED AS AUSTRALIA’S FIRST HEALTHTECH START-UP TO GRADUATE FROM PRESTIGIOUS GLOBAL CREATIVE DESTRUCTION LAB (CDL) PROGRAM, BRINGING THEIR WORLD-FIRST PRECISION MEDICINE TOOL FOR MANAGING CHRONIC RESPIRATORY DISORDERS CLOSER TO REALITY

Diag-Nose.io 3 mins read
Eldin Rostom, Co-Founder (R) and Dr David Yen, Co-CMO & Co-Founder (L). Credit: Creative Destruction Lab

MELBOURNE, Victoria, 28th June 2023 - Diag-Nose.io, a pioneering Australian healthtech start-up has emerged triumphant from four intense elimination rounds in the highly competitive Creative Destruction Lab (CDL) program in Seattle, making it the first Australian company to graduate in the Computational Health Stream and only one of a few Australian companies since the program started in 2012.

Eldin Rostom, CEO and Co-Founder of Diag-Nose.io said “The CDL program has enabled us to move onto the next phase of clinical development with a robust strategy to expedite the commercialisation of our suite of AI-enabled diagnostic tools, to exponentially improve the clinician and patient experience when it comes to managing chronic nasal and airway disorders”.

Current research shows that chronic respiratory disorders, including chronic sinusitis and asthma, consist of multiple biological subtypes, or “endotypes” which can be detected on a molecular level to predict and monitor treatment response. Yet, in clinical practice, treatment decisions are still primarily based on observable traits or symptoms, resulting in numerous failed therapies and prolonged patient distress that can last for several years.

“Diag-Nose.io’s product, the RhinoMAP, will leverage proprietary chemistry and AI to map out these endotypes for each patient resulting in a better patient experience stemming from faster treatment decisions, reduced costs and improved overall outcomes. This is especially important today since the recent approval of antibody therapies in the respiratory space.” Rostom explained.

Over a third of Australia's population is impacted by chronic respiratory conditions, including chronic sinusitis, asthma, and allergic rhinitis*. Among these, the two million individuals suffering from chronic sinusitis often experience severe symptoms that feel as debilitating as chronic heart failure or chronic back pain.

One of the mentors working with Diag-Nose.io, William Canestro, Managing Director of Washington Research Foundation commended the team on their vision and product saying “Diag-Nose.io provides a cutting-edge solution to the real world challenge of biologic treatment for chronic sinusitis and potentially other airway disorders. I’m excited to follow their progress as they spearhead personalized medicine in this space.”

The highly-prized CDL program brings together aspiring science and technology venture founders and seasoned mentors from across the globe for a nine month period where founders battle it out to survive through to graduation, earning a coveted spot among the program’s elite alumni. In 2022 alone, the CDL received more than 2,200 applications from 87 countries, and out of 650 ventures admitted, only 240 successfully graduated. Diag-Nose was one of only seven to graduate within their stream.

“We were very fortunate to be a part of this extraordinary program which enabled us to strategically deconstruct our go-to-market strategy into a series of actionable near-term initiatives to demonstrate early commercial proof points.  Through this approach, we will build significant momentum in smaller beach-head markets which can be leveraged into scaling our full suite of products and exponentially improve care for chronic nasal and airway disorders” Rostom said.

Diag-Nose.io’s mentoring team included: Dr. George Savage - Co-founder of Proteus Digital and President of Windmill Partners, Rhonda Rhyne - President & CEO of Prevencio, Douglas Beach - Chairman of Eavor Technologies Inc., Mark Adams - former COO of Adaptive Biotechnologies , Ben Wanamaker - VP Enterprise Strategy at Humana Inc., William Canestaro - Managing Director of Washington Research Foundation, Allison Gaw - Principal at Amplitude Ventures, Dr. Sheila Rege - Board Chair of American College of Radiation Oncology and Douglas Foster - Partner at Advanced Data Sciences LLC.

References:
* Australian Government, Department of Health. Chronic respiratory conditions Chronic respiratory conditions, Summary - Australian Institute of Health and Welfare (aihw.gov.au)


-ENDS-


Key Facts:

DIAG-NOSE.IO ANNOUNCED AS AUSTRALIA’S FIRST HEALTHTECH START-UP TO GRADUATE FROM PRESTIGIOUS GLOBAL CREATIVE DESTRUCTION LAB (CDL) PROGRAM.

- WORLD-FIRST SUITE OF AI-ENABLED DIAGNOSTIC TOOLS SET TO PERSONALISE TREATMENT DECISIONS FOR CHRONIC RESPIRATORY CONDITIONS AND IMPROVE QUALITY OF LIFE FOR MANY AUSTRALIANS.

- OVER ONE THIRD OF AUSTRALIA'S POPULATION IS IMPACTED BY CHRONIC RESPIRATORY CONDITIONS WITH MANY EXPERIENCING SEVERE DEBILITATING SYMPTOMS.


About us:

About Diag-Nose.io

Founded in 2020 after a world-class team of otolaryngologists, bioengineers and entrepreneurs met at the Stanford Medicine EENT Innovation Program, Diag-Nose.io’s founders are on a mission to improve a billion lives globally by significantly improving current diagnostic processes for  chronic airway and nasal disorders. Their world-first clinical decision support system utilises a unique combination of proprietary chemistry and AI to deliver personalised treatment pathways for clinicians and patients and is currently undergoing clinical studies in both Australia and the United States.

 

Diag-Nose.io founders

Eldin Rostom - CEO/Co-Founder

Dr Brian Wang - Co-CMO/Co-Founder

Dr David Yen - Co-CMO/Co-Founder

 

Dr Josie Xu - MSL/Co-Founder

About Creative Destruction Lab (CDL)

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. 


Founded in 2012 by Professor Ajay Agrawal at the University of Toronto’s Rotman School of Management, the program has expanded to ten sites across four countries: Oxford, Paris, Atlanta, Madison, Seattle, Vancouver, Calgary, Montreal and Halifax. The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over $28 billion CAD in equity value. 

 


Contact details:

For any questions in relation to this release or to organise interviews with spokepeople, please contact:


Nicole Papoutsis

nicole.papoutsis@gmail.com
0422 418 099

 

 

Media

More from this category

  • Medical Health Aged Care
  • 27/05/2024
  • 14:21
Dementia Australia

Community turns out in force to support people impacted by dementia

Thank you to Brisbane community members who turned up in force to the 2024 Memory Walk & Jog, showing their support for Australians living with dementia. More than 1,200 people walked, ran and jogged on Sunday 26 May raising an impressive total of $135,000! Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said it was a wonderful occasion and extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Brisbane community who turned out in such large numbers for another year. So many people…

  • Contains:
  • Medical Health Aged Care
  • 27/05/2024
  • 13:09
UNSW Sydney

Ozempic found to reduce risk of kidney disease and death in people with diabetes

A popular diabetes medication has been found to prevent kidney failure and reduce deaths in people with type 2 diabetes and chronic kidney disease. Antidiabetic medication semaglutide, more widely known by brand names Ozempic and Wegovy, significantly reduces the risk of kidney failure, substantial loss of kidney function and death from kidney or cardiovascular causes, an international clinical trial led by UNSW Sydney researchers has shown. The trial involving more than 3500 participants with type 2 diabetes and chronic kidney disease from 28 countries – including Australia, the USA and China – found a small weekly dose of semaglutide reduced…

  • Medical Health Aged Care
  • 27/05/2024
  • 12:24
Dementia Australia

Community turns out in force to support people impacted by dementia

Thank you to Perth community members who turned up in force to the 2024 Memory Walk & Jog, showing their support for Australians living with dementia. More than 1,000 people walked, ran and jogged on Sunday 26 May raising an impressive total of $140,000! Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said it was a wonderful occasion and extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Perth community who turned out in such large numbers for another year. So many people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.